6 news items
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
. Investor ContactJordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
& Corporate Communications+1 (650) 910-0427
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
, Investor Relations & Corporate Communications+1 (650) 910-0427
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
, Investor Relations & Corporate Communications(650) 910-0427
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
Vice President, Investor Relations & Corporate Communications(650) 910-0427
edes3kkf6xr4x7aosicah7wo6zelsf4ik
ALGS
27 Mar 24
& Corporate Communications(650) 910-0427
- Prev
- 1
- Next